Is MR cholangiopancreatography more effective than endoscopic ultrasound in diagnosing choledocholithiasis?

Choledocholithiasis, or common bile duct stones (CBDS), is a recurrent gallstone disease requiring accurate diagnosis to prevent potential severe complications such as pancreatitis or cholangitis. This systematic review evaluates the diagnostic performance of MR cholangiopancreatography (MRCP) versus endoscopic ultrasound (EUS) in detecting CBDS.

MRCP, a non-invasive imaging modality recommended by NICE for initial evaluation, offers high specificity but reduced sensitivity for small or distal stones. Conversely, EUS demonstrates superior sensitivity, particularly for stones missed by MRCP, and allows immediate therapeutic intervention via endoscopic retrograde cholangiopancreatography (ERCP). Across multiple studies, EUS sensitivity ranged from 90-100%, while MRCP varied between 33-81%, with specificity generally higher for MRCP. Negative predictive value was markedly better for EUS (up to 93%) compared to MRCP (around 43%).

Timely imaging significantly reduces unnecessary ERCP procedures and associated complications. Combined or sequential use of MRCP and EUS enhances diagnostic accuracy, achieving sensitivity and specificity near 100%. Cost-effectiveness analyses suggest MRCP may offer economic advantages for the NHS, potentially saving millions annually, although EUS remains more diagnostically reliable. Technical factors, operator expertise and patient tolerance influence modality choice.

In conclusion, while MRCP is valuable for initial screening, EUS surpasses MRCP in overall diagnostic accuracy, especially for small or radiolucent stones. Optimal strategies may involve tailored use of both modalities to improve outcomes and resource efficiency.

To download and read this article as a pdf please sign up to our newsletter.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.